Here is another pre-ASH press release from a drug company, ImmunoGen, I found posted on Marketwatch.com yesterday:
Nov. 17, 2010
ImmunoGen, Inc. Announces Clinical Data Presentations at the 52nd ASH Annual Meeting and Exposition
WALTHAM, Mass., Nov 17, 2010 (BUSINESS WIRE) — ImmunoGen, Inc., a biotechnology company that develops targeted antibody-based anticancer products, today announced that three presentations of clinical data for compounds employing its Targeted Antibody Payload (TAP) technology will be made at the 52nd ASH Annual Meeting and Exposition to be held in Orlando, Florida, December 4-7, 2010.
“Findings from three clinical trials with two TAP compounds are being reported at ASH this year, reflecting the start in the rapid growth in the number of trials underway with TAP compounds that began last year,” commented Daniel Junius, President and CEO. “Initial data will be reported from the first trial to assess IMGN901 used as part of a combination regimen — in this case, to treat multiple myeloma — which will complement the trial we’re starting that assesses it in combination with approved therapies to treat small-cell lung cancer. Updated data will be reported from the IMGN901 monotherapy trial as well as from the first trial conducted with Biotest’s TAP compound, BT-062, which is now being assessed, as planned, in a second trial using a more frequent dosing regimen.”
Presentations on Dec. 4 from 5:30-7:30 pm ET in Hall A3/A4:
“Phase I Study of Lorvotuzumab Mertansine (IMGN901) In Combination with Lenalidomide and Dexamethasone In Patients with CD56-Positive Relapsed or Relapsed/Refractory Multiple Myeloma — A Preliminary Safety and Efficacy Analysis of the Combination” (Abstract #1934, Poster board #I-914). “Efficacy Analysis from Phase I Study of Lorvotuzumab Mertansine (IMGN901), Used as Monotherapy, In Patients with Heavily Pre-Treated CD56-Positive Multiple Myeloma — A Preliminary Efficacy Analysis” (Abstract #1962, Poster board #I-942).
Presentation on Dec. 5 from 6:00-8:00 pm ET in Hall A3/A4:
“BT062, An Antibody-Drug Conjugate Directed Against CD138, Shows Clinical Activity In a Phase I Study in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma” (Abstract #3060, Poster board #II-940).
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer therapeutics using the Company’s expertise in tumor biology, monoclonal antibodies and potent cancer-cell killing agents. The Company’s TAP technology uses monoclonal antibodies to deliver one of ImmunoGen’s proprietary cancer-cell killing agents specifically to tumor cells. There are currently seven TAP compounds in the clinic, with a wealth of clinical data reported with the technology. ImmunoGen’s collaborative partners include Amgen, Bayer Schering Pharma, Biogen Idec, Biotest, Genentech (a member of the Roche Group), Novartis, and sanofi-aventis. The most advanced compound using ImmunoGen’s TAP technology, trastuzumab-DM1 (T-DM1), is in Phase III testing through the Company’s collaboration with Genentech. More information about ImmunoGen can be found at www.immunogen.com.
All are only Phase I studies, so nothing which will help multiple myeloma patients right away. Still, definitely worth following-up on.
Feel good and keep smiling! Pat